AOD-9604 Dosage Guide: Fat Loss Peptide Reconstitution, Syringe Units & Phase 2 Research

AOD-9604 research overview: Phase 2b fat loss data, typical dose range (500 mcg/day), reconstitution setup for 5mg vials, and syringe unit calculator.

TL;DR — AOD-9604 Peptide at a Glance

• 16-amino acid C-terminal fragment of human growth hormone (residues 176–191) with a disulfide modification
• Stimulates lipolysis and inhibits lipogenesis through mechanisms independent of IGF-1 or insulin signaling
• Typical research dose: 300 mcg/day subcutaneous, administered in the fasted state
• Does not elevate blood glucose, stimulate IGF-1 production, or cause the diabetogenic effects associated with full-length HGH
• 🧮 Calculate your AOD-9604 dose now →

⚠️ Research Disclaimer: AOD-9604 is a research compound not approved by the FDA for human use. All information on this page is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before use.

AOD-9604 peptide was developed by Metabolic Pharmaceuticals in Australia with an elegant premise: if growth hormone's anabolic effects (mediated through IGF-1 signaling) and its lipolytic effects are separable at the molecular level, it should be possible to isolate the fat-burning component and develop it as a targeted obesity treatment without the metabolic complications of full-length HGH. The research that validated this premise identified a specific region of the HGH molecule — amino acids 176 through 191, at the C-terminal end — as the domain responsible for the fat metabolism effects of growth hormone. AOD-9604 is a synthetic version of this fragment (also known as HGH Fragment 176-191) with an additional disulfide bond modification that enhances stability, and it represents one of the most mechanistically specific peptides studied for fat loss research.

What distinguishes AOD-9604 from virtually every other approach to fat loss research is its selectivity profile. Full-length HGH, when administered pharmacologically, simultaneously stimulates lipolysis, promotes IGF-1 production (driving anabolism and potential tumor growth), causes insulin resistance, and raises blood glucose. GLP-1 receptor agonists like semaglutide reduce appetite and slow gastric emptying as their primary mechanism, with fat loss as a downstream consequence. AOD-9604 acts directly on adipocytes to stimulate fat breakdown without triggering IGF-1 production or affecting glucose homeostasis — a profile that made it an attractive clinical candidate when Metabolic Pharmaceuticals advanced it through Phase 2 and Phase 3 clinical trials in the mid-2000s, making it the most clinically tested HGH fragment peptide in existence.

How AOD-9604 Stimulates Fat Loss at the Cellular Level

The lipolytic mechanism of AOD-9604 is mediated through beta-3 adrenergic receptor activation and downstream cyclic AMP (cAMP) signaling in adipose tissue, mirroring the pathway activated by the relevant domain of full-length HGH. When AOD-9604 binds its receptor on adipocytes, adenylyl cyclase activity increases, cAMP rises, and hormone-sensitive lipase (HSL) is phosphorylated and activated. Activated HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol — the fundamental process of lipolysis. These liberated fatty acids are then available for beta-oxidation in peripheral tissues (particularly skeletal muscle during activity) or re-esterification if energy demands are low.

Simultaneously, AOD-9604 inhibits acetyl-CoA carboxylase, the rate-limiting enzyme in de novo lipogenesis. This dual action — stimulating fat breakdown while inhibiting new fat synthesis — creates a coordinated anti-adipogenic effect that in vitro studies have shown to be both statistically and practically significant. Research in 3T3-L1 preadipocyte cell lines demonstrated that AOD-9604 treatment reduced lipid accumulation during differentiation by approximately 30–40% compared to controls.

Critically, this mechanism operates without engaging the IGF-1R signaling pathway. In cell-based assays comparing AOD-9604 to full-length HGH, AOD-9604 produced no measurable increase in IGF-1 production and showed no cross-reactivity with insulin receptors. In vivo studies in obese rodent models confirmed that AOD-9604 did not alter fasting insulin levels, fasting glucose, or insulin tolerance test results — findings that were replicated in the Phase 2 human clinical data. This insulin-neutrality profile is what most clearly distinguishes AOD-9604 from HGH in a clinical research context, and from GLP-1 agonists in terms of mechanism. The GLP-1 peptides comparison guide discusses the mechanistic landscape of GLP-1 class compounds for broader context on fat loss peptide research.

AOD-9604 Clinical Development: Phase 2 and Phase 3 Trial Data

AOD-9604 represents an unusually well-documented research peptide by virtue of having progressed through formal clinical development. Metabolic Pharmaceuticals conducted Phase 2 trials (published in Obesity Research, 2004) enrolling obese adults in a 12-week randomized, placebo-controlled study. Participants receiving 1 mg/day oral AOD-9604 lost a statistically significant greater amount of weight than placebo (approximately 2.0 kg more over 12 weeks), with no adverse effects on insulin sensitivity, blood glucose, or IGF-1 levels. The study confirmed in humans what the preclinical data had suggested: AOD-9604 selectively targets adipose tissue metabolism without systemic metabolic disruption.

The Phase 3 trial (KIORA trial) enrolled approximately 500 participants across multiple sites in Australia and New Zealand, testing both subcutaneous injection and oral tablet formulations. While the primary endpoint (percentage body fat reduction) showed a positive trend, the trial did not achieve statistical significance on the primary endpoint with the oral formulation, and Metabolic Pharmaceuticals did not advance the program to regulatory submission. The injectable formulation data was not the primary arm of the Phase 3 trial. This outcome — modest efficacy in the clinical setting despite compelling preclinical and Phase 2 data — is instructive for researchers studying obesity pharmacology and the translation challenges between animal models and human studies.

The Phase 2 Heatherton et al. study (2004) remains the primary clinical reference for researchers. It established the 1 mg/day oral dose as the optimal clinical dose (lower and higher doses showed less efficacy in the dose-ranging arms), and provided the human safety data confirming the absence of IGF-1 elevation — a finding that distinguished AOD-9604 from any growth hormone-based therapy. Researchers interested in comparing AOD-9604 against newer metabolic peptides should also review the tirzepatide dosage guide for context on dual GIP/GLP-1 agonism.

AOD-9604 Reconstitution: Volumes, Concentrations, and Syringe Math

AOD-9604 dissolves well in bacteriostatic water at standard pH and does not require acetic acid pre-treatment. The lyophilized powder is typically supplied in 2 mg or 5 mg vials. For a 2 mg vial, reconstituting with 2 mL of BAC water yields a convenient 1,000 mcg/mL (1 mg/mL) stock solution. For a 5 mg vial, 5 mL of BAC water gives the same concentration.

AOD-9604 Reconstitution Table (2 mg vial)

For the most common research dose of 300 mcg administered once daily, a 2 mg vial reconstituted in 2 mL (1 mg/mL) yields approximately 6–7 injections before the vial is depleted. Store reconstituted solution at 2–8°C; use within 4 weeks. Use the reconstitution calculator to customize calculations for any vial size.

AOD-9604 vs Other Fat Loss Peptides: Mechanism Comparison

Understanding AOD-9604 within the broader landscape of fat loss research compounds requires distinguishing between the primary mechanisms at play across different compound classes.

Fat Loss Peptide Mechanism Comparison

The table illustrates AOD-9604's unique niche: it is the only fat loss research compound with a direct adipocyte mechanism that is simultaneously IGF-1-neutral and glucose-neutral. This profile makes it particularly interesting for research contexts where the confounding effects of GLP-1 agonists (appetite suppression, GI side effects) or HGH (anabolism, insulin resistance) would complicate interpretation of fat loss-specific data. Researchers comparing GLP-1 class compounds should review the GLP-1 peptides compared guide for a more detailed analysis of that compound class.

AOD-9604 Dosage Protocols: What the Research Literature Supports

The 300 mcg/day subcutaneous dose for AOD-9604 is the most commonly cited figure in research literature, derived from the injectable dose-ranging data that paralleled the oral clinical development program. Administration in the fasted state (morning, before food) is preferred to maximize lipolytic signaling, as the concurrent insulin elevation from a meal actively suppresses hormone-sensitive lipase activity and would blunt the peptide's pro-lipolytic effects.

In rodent models, doses were weight-based (typically 100–500 mcg/kg) and administered either subcutaneously or intraperitoneally, with obese mice showing the greatest lipolytic response — consistent with the higher basal lipid availability in adipose tissue. When scaling across species, researchers should use allometric scaling rather than simple body weight ratios; the dosage calculator supports surface-area-based dose conversion for translational research applications.

Some research protocols have explored fractionated dosing (150 mcg twice daily) as an alternative to once-daily 300 mcg administration, theorizing that two smaller stimuli may produce more sustained cAMP activation than a single larger pulse. The comparative data on split vs. once-daily dosing is limited, and the clinical development program focused exclusively on once-daily administration.

How to Calculate AOD-9604 Doses with Our Free Peptide Calculator

The most common source of dosing error in AOD-9604 research protocols is the unit conversion between micrograms (mcg) and the markings on an insulin syringe. A 300 mcg dose from a 1 mg/mL solution represents 0.3 mL — or 30 IU on a 1 mL insulin syringe. This is a manageable volume, but varying the reconstitution volume (e.g., using 4 mL of BAC water instead of 2 mL) changes the syringe marking to 60 IU, which could be misread as the dose having doubled.

The free peptide reconstitution calculator handles all unit conversions automatically. Enter your vial size, BAC water volume, and target dose, and the tool returns both the volume in mL and the precise insulin syringe marking. For comparative dosing across the weight-loss peptide class, the dosage calculator allows side-by-side dose comparison.

Frequently Asked Questions About AOD-9604 Peptide

Q: What is AOD-9604, and how does it differ from HGH? A: AOD-9604 is a 16-amino acid synthetic fragment corresponding to residues 176–191 of human growth hormone, modified with a disulfide bond for stability. Unlike full-length HGH, AOD-9604 does not stimulate IGF-1 production, does not cause insulin resistance, and does not raise blood glucose levels. It selectively activates the fat metabolism pathway of HGH — stimulating adipocyte lipolysis and inhibiting lipogenesis — without triggering any of the anabolic or diabetogenic effects associated with pharmacological HGH doses.

Q: How does AOD-9604 cause fat loss at the cellular level? A: AOD-9604 activates beta-3 adrenergic receptors on adipocytes, triggering a cAMP-mediated signaling cascade that phosphorylates and activates hormone-sensitive lipase (HSL). Activated HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids available for peripheral oxidation. Simultaneously, AOD-9604 inhibits acetyl-CoA carboxylase, the rate-limiting enzyme in de novo fat synthesis, creating a dual anti-adipogenic effect at the cellular level.

Q: Does AOD-9604 affect blood sugar or insulin sensitivity? A: Research data, including human Phase 2 clinical trial data from Metabolic Pharmaceuticals, consistently shows that AOD-9604 has no measurable effect on fasting glucose, insulin levels, or insulin tolerance. This distinguishes it from full-length HGH (which causes insulin resistance) and makes it a useful research tool when metabolic effects on glucose homeostasis would confound the experimental design. This glucose-neutrality was a key differentiating feature in the compound's clinical development rationale.

Q: How do you reconstitute AOD-9604 for research use? A: AOD-9604 dissolves readily in bacteriostatic water without requiring acetic acid. Add the desired volume of BAC water to the lyophilized vial (2 mL to a 2 mg vial gives a 1 mg/mL concentration), gently swirl until dissolved, and store at 2–8°C. The reconstituted solution is stable for approximately 4 weeks under refrigeration. Avoid freezing the reconstituted solution repeatedly, as this can accelerate degradation.

Q: How is AOD-9604 different from semaglutide for fat loss research? A: AOD-9604 and semaglutide act through entirely different mechanisms. AOD-9604 acts directly on adipocytes to stimulate lipolysis — a peripheral fat metabolism mechanism. Semaglutide acts centrally and peripherally as a GLP-1 receptor agonist, primarily reducing food intake through appetite suppression and gastric emptying delay, with fat loss as a downstream metabolic consequence. AOD-9604 produces no appetite suppression, no GI side effects, and no effect on glucose metabolism, while semaglutide has all of these effects. The two represent complementary research tools for studying different aspects of fat metabolism.

All content is for educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions